Outcomes/Comparative-Effectiveness Research

Sunday, June 5 | 4:15 AM - 5:45 PM
Room 214A

Moderators are:
William C. Lavely, MD, Vanderbilt University in Nashville, Tenn.; and
Pradeep G. Bhambhvani, MD, University of Alabama at Birmingham.

Studies to be presented are:
  • Cost-effectiveness of FDG PET/CT in patients with Gram[+] bacteraemia;
  • Remnant ablation success and differentiated thyroid carcinoma outcome in stage III/IV patients: Recombinant human thyrotropin vs. thyroid hormone withdrawal;
  • The incidence of clinically important PET-negative CT-positive findings in a large clinical PET/CT practice;
  • Ga-68 DOTATOC PET/CT and In-111-DTPA-Octreotide SPECT for staging of enteropancreatic neuroendocrine tumors: Evaluation of costs and consequential costs;
  • Outpatient treatment of hyperthyroidism: How to protect the public?;
  • Direct comparison of neck pinhole dual-tracer and dual-phase sestamibi accuracies with and without SPECT/CT for parathyroid adenoma localization; and
  • Comparison of 2-deoxy-2-[F-18]fluoro-D-glucose uptake in the cerebellum and liver, reference organs for assessment of glucose metabolism, in oncologic patients.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.